Annals of Oncology. 22(7):1622–1627, JULY 2011

DOI: 10.1093/annonc/mdq626

,  

PMID: 21228334

Issn Print: 0923-7534

Publication Date: July 2011


Share this on facebook   Share this on Twitter   Share this on LinkedIn   Email this article  



Print

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

T. Witzig;J. Vose;P. Zinzani;C. Reeder;R. Buckstein;J. Polikoff;R. Bouabdallah;C. Haioun;H. Tilly;P. Guo;D. Pietronigro;A. Ervin-Haynes;M. Czuczman;

+ Author Information


    loading  Checking for direct PDF access through Ovid

Abstract

Background: Lenalidomide is an immunomodulatory agent with antitumor activity in B-cell malignancies. This phase II trial aimed to demonstrate the safety and efficacy of lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular grade 3 lymphoma (FL-III), or transformed lymphoma (TL).Methods: Patients received oral lenalidomide 25 mg on days 1–21 every 28 days as tolerated or until progression. The primary end point was overall response rate (ORR).Results: Two hundred and seventeen patients enrolled and received lenalidomide. The ORR was 35% (77/217), with 13% (29/217) complete remission (CR), 22% (48/217) partial remission, and 21% (45/217) with stable disease. The ORR for DLBCL was 28% (30/108), 42% (24/57) for MCL, 42% (8/19) for FL-III, and 45% (15/33) for TL. Median progression-free survival for all 217 patients was 3.7 months [95% confidence interval (CI) 2.7–5.1]. For 77 responders, the median response duration lasted 10.6 months (95% CI 7.0–NR). Median response duration was not reached in 29 patients who achieved a CR and in responding patients with FL-III or MCL. The most common adverse event was myelosuppression with grade 4 neutropenia and thrombocytopenia in 17% and 6%, respectively.Conclusion: Lenalidomide is well tolerated and produces durable responses in patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma.

Related Topics

    Related Articles

        loading  Loading Related Articles